Navigation Links
Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
Date:10/16/2007

- Isis will own 18 percent of Altair and will receive milestones and

royalties on antisense drugs developed by Altair

- Altair to conduct clinical development of ISIS 369645 for asthma

CARLSBAD, Calif. and SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Thomas, McNerney & Partners, LLC, announced today that Altair Therapeutics Inc., a new venture capital-funded biotechnology company, has been created to focus on the discovery, development and commercialization of Isis' antisense drugs to treat asthma and other respiratory conditions. Isis has granted an exclusive worldwide license to Altair for the development and commercialization of ISIS 369645, an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment of asthma. Isis and Altair will also be collaborating to discover drugs directed to other promising targets for the treatment of respiratory conditions. Isis will own 18 percent of Altair in the form of preferred stock. Furthermore, as ISIS 369645 and other drugs arising out of the research collaboration progress, Altair will pay Isis development milestones and royalties.

"Altair is assembling a focused team of experts in both antisense drug discovery and development and respiratory conditions to advance antisense drugs, including ISIS 369645," said Jeff Jonas, M.D., Executive Vice President of Isis. "Our robust antisense technology allows us to continue to discover and validate many more drug candidates than we can advance ourselves. Altair is the most recent example of our satellite company strategy; through this strategy we expand therapeutic applications for antisense drugs while focusing our internal resources in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Jellyfish partners for sales tracking technology
4. GE Healthcare partners with UNC on breast cancer imaging research
5. Manufacturing partnership will move into biotech and biomedical spaces
6. Fergus joins Baird Venture Partners, Caden Bio
7. Avolte Venture Partners reaches capital goal
8. NimbleGen partners with UK biotech firm
9. Big pharma seeks Wisconsin biotech partnerships
10. Thompson in partnership to build ethanol plant
11. Johnson Controls partners on car satellite linkup

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...e/ -- Reportlinker.com announces that a new market..., Emerging Clinical Trial Locations - Eastern E... and regulatory environment ,, http://www.rep...ations---Eastern-Europe-Market-dynamics-and-the-ch... ,, Over the last decade pharmaceutical and bio...
(Date:12/1/2009)...ire/ -- Expanding its European reach for bacterial... appointed Lake Chemicals and Minerals of England ...ingham, England. ,, Osprey breeds trillions of... waste water, and environmental markets. Its bacte..., and clean up industrial and marine spills. In ag...
(Date:12/1/2009)...agrees to migrate their Microsoft Dynamics SL clie...rgy Business Solutions to maintain quality service...ecember 1, 2009 -- Synergy Business Solutions anno... SL practice of Congruent Software, a Bellevue, WA...ary due to a change in Congruent Software’s ...
(Date:12/1/2009)... /PRNewswire-Asia-FirstCall/ -- China Sky One Medi...") (Nasdaq: CSKI ), a leading,fully integrated ph...-the-counter drugs in the People,s Republic of Chi...ngaged Guangdong Mediacy Kind Medical Devices,Indu...sive sales agent for the,Company,s AMI Diagnostic ...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3
... - Probing a class of enzymes routinely used to s...team of Wisconsin scientists has found a new way t...ritical anticancer agents and antibiotics. , ,Writ...a team led by Jon S. Thorson, a professor of pharm...-Madison , describes the discovery of a simple pro...
...s. - Republican gubernatorial candidate Mark Gre...n state money to the WiCell Research Institute t...ving stem cells that don,t involve the destruction... was swift, with the governor,s campaign stating t... technique. , ,Appearing at the home of Tom and Da...
... - Madison,s ability to build a community of life...llinois biotechnology company chose to relocate he...al led by Baird Venture Partners . , ,The company...l. into the New Venture Center on the Fitchburg T...as spun out of Northwestern University , has deve...
Other Biology Technology:UW finds new path to anti-cancer agents 2UW finds new path to anti-cancer agents 3Green unveils $25 million stem cell plan 2Green unveils $25 million stem cell plan 3Biotech talent drew venture-funded firm to Madison 2Biotech talent drew venture-funded firm to Madison 3
(Date:11/30/2009)...rleans, LA Researchers from LSU Health Sciences C...Kennedy Shriver National Institute of Child Health...Public Health, Brigham and Women,s Hospital, and H...me that drinking more than 5 servings of sugar- sw...significantly elevate the risk of developing diabe...
(Date:11/30/2009)...EN, N.J. - The inaugural Global Conference on Sys..., 2009, in Washington, DC, focuses on the converge... of critical importance to society. , The go...search activity around targeted complex systems, e...r,s topic includes Critical Infrastructure Systems...
(Date:11/30/2009)...advantage of lower early bird registration rates a...is congress of 2010 at http://www.iofwco-ecceo10....ss of the International Osteoporosis Foundation (I...omic Aspects of Osteoporosis and Osteoarthritis (E...e world are expected to attend. The exciting scien...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2Drugs against winter vomiting disease one step closer 48451 1Drugs against winter vomiting disease one step closer 48451 2New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 1New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 2DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 1DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 2DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 3
...ide biologists researching the behavior of field c...crickets remember attractive males based on the la...g mates. , The researchers found that female cric...ess of available males around them with other inco...ating. , The finding shows that social learning ...
..., 2009) EPA has announced the university teams who...(P3) competition. The P3 award competition encoura...tive ways to tackle global environmental challenge...ich is why each winner receives funding up to $75,...c innovation has long been a driving force behind ...
...gton University in St. Louis are bringing the mini...oupling USB-based ultrasound probe technology with...ional platform and a medical imaging device that f...Ph.D., Washington University Associate Professor o... Washington University Research Associate in Compu...
Other Biology News:Remembrance of things past influences how female field crickets select mates 2Remembrance of things past influences how female field crickets select mates 3EPA's P3 award winners celebrate a green future 2Ultrasound imaging now possible with a smartphone 2Ultrasound imaging now possible with a smartphone 3
CORNING IVF CULTURE DISH, 60 X 15MM, PS, STERILE from Sigma-Aldrich
DAPI from KPL
...pplied with two sets of glass plates, bar clamp, a... Special features of these units are:, safety inte...ervoirs , upper and lower reservoirs have drains w...buffer solutions , leveling base with bubble level...
...-HETE is a cytochrome P450 (CYP450) metabolite pos...cerebral vasculature. In rat cerebral microvessels...ure-induced autoregulatory vasoconstriction. 20-HE.... The concentration of free 20-HETE (20-40 pg/ml i...
Biology Products: